James Hay is a Director in the Healthcare group in London, with a focus on Life Sciences and Life Science Services.
He advises clients across the full value chain, from active pharmaceutical ingredients through formulation development and manufacturing of finished dose forms for small molecules, and bioprocessing tools and services for biologics and emerging modalities, including Cell & Gene Therapy. As a result, his clients include companies in the Chemicals, Industrials and traditional Healthcare sectors.
Prior to joining Lazard, James was part of the Life Sciences corporate finance advisory business at Deloitte. Prior to Deloitte, James was the lead Pharmaceutical & Biotechnology equity research analyst at a leading U.K. asset manager covering European Pharmaceutical & Biotechnology companies and has also worked with University technology transfer offices in the U.K. and U.S.
James is a CFA charterholder and holds a B.Sc. in Medicinal Biology & Genomics from the University of St. Andrews.
Our offices in the United Kingdom
Lazard has been a leading player in the United Kingdom's financial centre since the firm opened its first London office in 1877. Today, the U.K. remains one of the largest operations in Lazard’s global network.
Based in the heart of one of the world’s most international and connected financial hubs, with unrivalled access to global markets, Lazard U.K. advises clients on strategic matters including mergers and acquisitions, restructurings, debt and capital structure and capital raising.
Lazard's client relationships are built on trust and discretion, drawing on 175 years of experience working with leading businesses globally.